Dr Reddys Laboratories Share Price
Sector: Biotechnology & Drugs
1320.20 -20.65 (-1.54%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1315.00
Today’s High
1332.60
52 Week Low
1025.90
52 Week High
1420.20
1321.50 -20.10 (-1.50%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1314.60
Today’s High
1333.70
52 Week Low
1020.00
52 Week High
1421.49
Key Metrics
- Market Cap (In Cr) 110483.92
- Beta 0.38
- Div. Yield (%) 0.6
- P/B 3.33
- TTM P/E 16.85
- Peg Ratio 0.53
- Sector P/E 22.65
- D/E 0
- Open Price 1327.95
- Prev Close 1340.85
Dr Reddys Laboratories Analysis
Price Analysis
-
1 Week2.15%
-
3 Months15.2%
-
6 Month-0.69%
-
YTD-3.38%
-
1 Year10.36%
Risk Meter
- 23% Low risk
- 23% Moderate risk
- 23% Balanced Risk
- 23% High risk
- 23% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 7
- 7
- 7
- 6
- Buy
- 8
- 8
- 8
- 8
- Hold
- 8
- 8
- 9
- 8
- Sell
- 8
- 8
- 8
- 8
- Strong Sell
- 3
- 3
- 3
- 4
- Total
- 34
- 34
- 35
- 34
Dr Reddys Laboratories News
Prashanth Tapse of Mehta Equities suggests THESE 3 stocks to buy in short term
3 min read . 13 Jun 2025Dr Reddy’s to cut workforce cost by 25%? Here's what the drugmaker says
2 min read . 15 Apr 2025Dr Reddys Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 32643.9
- Selling/ General/ Admin Expenses Total
- 13947.6
- Depreciation/ Amortization
- 1703.7
- Total Operating Expense
- 25648.1
- Operating Income
- 6995.8
- Net Income Before Taxes
- 7679.5
- Net Income
- 5725.2
- Diluted Normalized EPS
- 67.94
- Period
- 2025
- Total Assets
- 49426.6
- Total Liabilities
- 15877
- Total Equity
- 33549.6
- Tangible Book Valueper Share Common Eq
- 271.1
- Period
- 2025
- Cashfrom Operating Activities
- 4642.8
- Cashfrom Investing Activities
- -5102.1
- Cashfrom Financing Activities
- 1185.5
- Net Changein Cash
- 748.6
- Period
- 2024
- Total Revenue
- 28011.1
- Selling/ General/ Admin Expenses Total
- 9202.6
- Depreciation/ Amortization
- 1470
- Total Operating Expense
- 21548
- Operating Income
- 6463.1
- Net Income Before Taxes
- 7201
- Net Income
- 5577.9
- Diluted Normalized EPS
- 66.08
- Period
- 2024
- Total Assets
- 38863.8
- Total Liabilities
- 10609
- Total Equity
- 28254.8
- Tangible Book Valueper Share Common Eq
- 288.35
- Period
- 2024
- Cashfrom Operating Activities
- 4543.3
- Cashfrom Investing Activities
- -4028.3
- Cashfrom Financing Activities
- -376.3
- Net Changein Cash
- 132.8
- Period
- 2023
- Total Revenue
- 24669.7
- Selling/ General/ Admin Expenses Total
- 8204.8
- Depreciation/ Amortization
- 1250.2
- Total Operating Expense
- 19449.8
- Operating Income
- 5219.9
- Net Income Before Taxes
- 6048.5
- Net Income
- 4507.3
- Diluted Normalized EPS
- 55.89
- Period
- 2023
- Total Assets
- 32285.1
- Total Liabilities
- 8999
- Total Equity
- 23286.1
- Tangible Book Valueper Share Common Eq
- 236.72
- Period
- 2023
- Cashfrom Operating Activities
- 5887.5
- Cashfrom Investing Activities
- -4137.3
- Cashfrom Financing Activities
- -2686.1
- Net Changein Cash
- -907.3
- Period
- 2022
- Total Revenue
- 21545.2
- Selling/ General/ Admin Expenses Total
- 7339.9
- Depreciation/ Amortization
- 1165.2
- Total Operating Expense
- 18942.7
- Operating Income
- 2602.5
- Net Income Before Taxes
- 3061.4
- Net Income
- 2182.5
- Diluted Normalized EPS
- 33.19
- Period
- 2022
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 192.39
- Period
- 2022
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021
- Total Revenue
- 19047.5
- Selling/ General/ Admin Expenses Total
- 6385.1
- Depreciation/ Amortization
- 1228.8
- Total Operating Expense
- 16402.2
- Operating Income
- 2645.3
- Net Income Before Taxes
- 2883.5
- Net Income
- 1951.6
- Diluted Normalized EPS
- 28.55
- Period
- 2021
- Total Assets
- 26616.8
- Total Liabilities
- 8975.1
- Total Equity
- 17641.7
- Tangible Book Valueper Share Common Eq
- 163.61
- Period
- 2021
- Cashfrom Operating Activities
- 3570.3
- Cashfrom Investing Activities
- -2266
- Cashfrom Financing Activities
- -29.8
- Net Changein Cash
- 1285.8
- Period
- 2020
- Total Revenue
- 17517
- Selling/ General/ Admin Expenses Total
- 5881
- Depreciation/ Amortization
- 1163.1
- Total Operating Expense
- 16203
- Operating Income
- 1314
- Net Income Before Taxes
- 1885.7
- Net Income
- 2026
- Diluted Normalized EPS
- 37.52
- Period
- 2020
- Total Assets
- 23225.3
- Total Liabilities
- 7626.5
- Total Equity
- 15598.8
- Tangible Book Valueper Share Common Eq
- 149.93
- Period
- 2020
- Cashfrom Operating Activities
- 2984.1
- Cashfrom Investing Activities
- -492.3
- Cashfrom Financing Activities
- -2515.9
- Net Changein Cash
- -26.6
- Period
- 2025-03-31
- Total Revenue
- 8528.4
- Selling/ General/ Admin Expenses Total
- 3603.7
- Depreciation/ Amortization
- 454.7
- Total Operating Expense
- 6985.2
- Operating Income
- 1543.2
- Net Income Before Taxes
- 2005.2
- Net Income
- 1586.7
- Diluted Normalized EPS
- 19.83
- Period
- 2025-03-31
- Total Assets
- 49426.6
- Total Liabilities
- 15877
- Total Equity
- 33549.6
- Tangible Book Valueper Share Common Eq
- 271.1
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 4642.8
- Cashfrom Investing Activities
- -5102.1
- Cashfrom Financing Activities
- 1185.5
- Net Changein Cash
- 748.6
- Period
- 2024-12-31
- Total Revenue
- 8381.2
- Selling/ General/ Admin Expenses Total
- 3527.1
- Depreciation/ Amortization
- 471.4
- Total Operating Expense
- 6579.6
- Operating Income
- 1801.6
- Net Income Before Taxes
- 1874.3
- Net Income
- 1413.7
- Diluted Normalized EPS
- 16.94
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 8038.2
- Selling/ General/ Admin Expenses Total
- 3502.6
- Depreciation/ Amortization
- 397
- Total Operating Expense
- 6358.7
- Operating Income
- 1679.5
- Net Income Before Taxes
- 1917.4
- Net Income
- 1255.7
- Diluted Normalized EPS
- 15.85
- Period
- 2024-09-30
- Total Assets
- 46728.4
- Total Liabilities
- 15979.1
- Total Equity
- 30749.3
- Tangible Book Valueper Share Common Eq
- 242.74
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1781.1
- Cashfrom Investing Activities
- -3931.9
- Cashfrom Financing Activities
- 2569.1
- Net Changein Cash
- 417.7
- Period
- 2024-06-30
- Total Revenue
- 7696.1
- Selling/ General/ Admin Expenses Total
- 3384
- Depreciation/ Amortization
- 380.6
- Total Operating Expense
- 5946.8
- Operating Income
- 1749.3
- Net Income Before Taxes
- 1882.6
- Net Income
- 1392.4
- Diluted Normalized EPS
- 16.7
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 7113.8
- Selling/ General/ Admin Expenses Total
- 3206.2
- Depreciation/ Amortization
- 367.7
- Total Operating Expense
- 5648.7
- Operating Income
- 1465.1
- Net Income Before Taxes
- 1605.2
- Net Income
- 1309.8
- Diluted Normalized EPS
- 15.53
- Period
- 2024-03-31
- Total Assets
- 38863.8
- Total Liabilities
- 10609
- Total Equity
- 28254.8
- Tangible Book Valueper Share Common Eq
- 288.35
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4543.3
- Cashfrom Investing Activities
- -4028.3
- Cashfrom Financing Activities
- -376.3
- Net Changein Cash
- 132.8
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Dr Reddys Laboratories Technical
Moving Average
SMA
- 5 Day1320.25
- 10 Day1337.3
- 20 Day1301.95
- 50 Day1232.52
- 100 Day1200.21
- 300 Day1254.15
Dr Reddys Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Divis Laboratories
- 6598.55
- 13.65
- 0.21
- 6859.8
- 4396.6
- 175273.25
- Cipla
- 1513.6
- 3.6
- 0.24
- 1702
- 1310.05
- 122270.85
- Dr Reddys Laboratories
- 1320.2
- -20.65
- -1.54
- 1420.2
- 1025.9
- 110483.92
- Torrent Pharmaceuticals
- 3213.05
- -12.7
- -0.39
- 3589.95
- 2755
- 108463.6
- Zydus Lifesciences
- 979.55
- 4.6
- 0.47
- 1323.9
- 797.05
- 98458.52
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Divis Laboratories
- 78.91
- 11.64
- 18.08
- 25.96
- Cipla
- 23.04
- 3.89
- 15.18
- 14.74
- Dr Reddys Laboratories
- 19.68
- 3.32
- 17.62
- 15.81
- Torrent Pharmaceuticals
- 55.83
- 14.18
- 22.03
- 14.14
- Zydus Lifesciences
- 20.68
- 4.05
- 17.48
- 16.73
Dr Reddys Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 09-May-25
- Audited Results, Dividend & Others
- 23-Jan-25
- Quarterly Results
- 05-Nov-24
- Quarterly Results
- 27-Jul-24
- Quarterly Results & Stock Split
- 07-May-24
- Audited Results & Final Dividend
- 30-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 10-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 24-Jul-25
- 09-May-25
- AGM
- 14-Sept-24
- 16-Aug-24
- POM
- 29-Jul-24
- 07-May-24
- AGM
- 15-Feb-24
- 15-Jan-24
- POM
- 16-Nov-23
- 16-Oct-23
- POM
- 27-Jul-23
- 10-May-23
- AGM
- 29-Jul-22
- 20-May-22
- AGM
- 29-Mar-22
- 25-Feb-22
- POM
- 28-Jul-21
- 20-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 09-May-25
- 10-Jul-25
- 10-Jul-25
- 8
- 07-May-24
- -
- 16-Jul-24
- 40
- 10-May-23
- -
- 11-Jul-23
- 40
- 19-May-22
- -
- 11-Jul-22
- 30
- 14-May-21
- -
- 09-Jul-21
- 25

- Ex-Splits
- Old FV
- New FV
- Description
- 28-Oct-24
- 5
- 1
- Stock Split from Rs. 5/- to Re. 1/-
